Cancer screening method

• US 7,820,386 B2
• Filed: 06/15/2007
• Issued: 10/26/2010
• Est. Priority Date: 06/15/2007
• Status: Expired due to Fees

• Current Assignee: National Defense Medical Center (Government of The Republic of China)
• Original Assignee: National Defense Medical Center (Government of The Republic of China)
• Inventors: Lai, Hung-Cheng
• Primary Examiner(s): BAUSCH, SARAE L
• Application Number:
  US11/764,051
• Publication Number:
  US 20080311570A1
• Time in Patent Office: 1,229 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/154 Methylation markers
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.

Claims

1. A method of screening for cervical cancer in a human patient comprising:

(i) obtaining a biological sample comprising cervical cells from the patient,

(ii) determining a degree of methylation of a CpG sequence of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1 in the sample, and

(iii) comparing a level of methylation of the CpG sequence of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1 in the sample with the level of methylation in normal cervical cells;

wherein a higher degree of methylation in the sample compared to normal cervical cells indicates an increased likelihood of cervical cancer.

2. A method of screening for cervical cancer as recited in claim 1, wherein a target gene SOX1 has a nucleotide sequence as depicted in SEQ ID No:

1.

3. A method of screening for cervical cancer as recited in claim 1, wherein a target gene PAX1 has a nucleotide sequence as depicted in SEQ ID No:

2.

4. A method of screening for cervical cancer as recited in claim 1, wherein a target gene LMX1A has a nucleotide sequence as depicted in SEQ ID No:

3.

5. A method of screening for cervical cancer as recited in claim 1, wherein a target gene NKX6-1 has a nucleotide sequence as depicted in SEQ ID No:

4.

6. A method of screening for cervical cancer as recited in claim 1, wherein a target gene WT1 has a nucleotide sequence as depicted in SEQ ID No:

5.

7. A method of screening for cervical cancer as recited in claim 1, wherein a target gene ONECUT1 has a nucleotide sequence as depicted in SEQ ID No:

6.